Is Healius out of the woods yet? Wrong question. The woods belong to the regulator.

 The Assay: IVD & Medical Diagnostics

One or two things that moved your market today | Friday, 24 July 2026 · ANZ edition

Healius's first half showed its clearest signs of life in two years, and the market barely blinked. Underlying EBITDA rose 13.1% to A$122.2m and EBIT swung back to a A$7.9m profit. Cost cutting, not volume, did the lifting. The balance sheet that nearly sank the company is already fixed: the A$965m Lumus sale cleared the debt entirely.

So why is the stock near 35 cents, at its lows for the year?

Because cost cuts can't touch the real problem. By April, pathology volumes had turned negative, and the federal budget offered no relief from the indexation freeze on most tests. Whether it's Healius, Sonic or ACL, the race to consolidate labs finished a few years ago. You don't cost-cut your way out of a structural funding gap forever, and the net cash cushion is already thinning. In June 25 they had A$57.2m and had burnt that down to A$11.6m by that December.

I don't think this is a turnaround story. It's the first visible symptom of a policy vice the government built itself.

The ACCC won't allow consolidation yet the MBS won't release more funding. It's a race to the bottom for the Australian pathology industry, and we're seeing it play out with Healius.

Not Enough Funding + Consolidated Market = No One Wins

A sector funded so tightly that only the fittest survive. They'll pick up the volume of the others when they go bankrupt, regardless of what the competition regulator wants.

The "scale" case for merging has largely run out. Pathology's efficiencies are front-loaded into the mega-lab, so bolting networks together now adds duplicate footprints faster than savings. That's the quiet reason ACL walking away looks smart in hindsight.

That leaves a three-horse race with one clear favorite: Sonic > Healius > ACL0.

The regulator's real risk isn't two players. It's a freeze pushing a weakened Healius into Sonic's orbit, leaving one player (Sonic) with overwhelming pricing leverage.

In Australian pathology that shows up not as higher sticker prices (Medicare sets those) but as thinner regional coverage, less bulk-billing, and gap fees on once-free tests. Same bill for the public, quieter route with no blowback.

What's the supplier read on this

Two opposing signals to hold at once.

Counterparty risk is receding: a debt-free, EBITDA-positive Healius converting ~100% to cash is a far safer customer than two years ago, and trade creditors get paid ahead of equity.

But pricing-power risk is building, and a takeover sharpens it. With a strategic review underway, Agilex already being marketed, and the whole company valued near A$254m, the PE playbook is obvious: buy cheap, strip the cash, reload with debt. A PE-owned or Sonic-absorbed Healius is a more leveraged, more cost-disciplined customer, harder on your pricing and terms. 

The consolidation that de-risks your invoice today squeezes your margin tomorrow.

The full year results are due to land in August. That will tell us if the net cash stabilizes. Any concrete move out of the strategic review is the real catalyst, not the earnings line.

Industry and market analysis, not investment advice.

References

1. Healius Limited, Half Year Results 1H FY26 presentation (18 Feb 2026). EBITDA A$122.2m (+13.1%), EBIT A$7.9m, revenue A$688.1m, pathology EBITDA A$117.4m. https://investorpa.com/announcement-pdf/20260218/257660.pdf

2. Healius Ltd (ASX:HLS) H1 FY26 earnings call highlights, net cash A$11.6m at 31 Dec 2025 (via Yahoo Finance / GuruFocus, 18 Feb 2026). https://finance.yahoo.com/news/healius-ltd-asx-hls-half-070037391.html

3. Business News Australia, "Healius shares slump 23pc as rising costs hit pathology giant, with federal budget no relief" (13 May 2026). Pathology volumes minus 0.4% to April; no indexation relief; shares to 37.2c. https://www.businessnewsaustralia.com/articles/healius-shares-slump-23pc-as-rising-costs-hit-pathology-giant-with-federal-budget-no-relief.html

4. Grafa, "Healius updates FY26 guidance amid strategic review" (12 May 2026). FY26 EBITDA guidance A$259 to 264m; strategic review of assets launched. https://grafa.com/en/news/australia/healius-updates-fy26-guidance-amid-review

5. Sharecafe, "Healius (HLS) announces FY25 results, meeting EBIT consensus" (21 Aug 2025). FY25 underlying EBITDA A$239.3m; net cash A$57.2m; debt repaid post-Lumus. https://www.sharecafe.com.au/2025/08/21/healius-hls-announces-fy25-results-meeting-ebit-consensus/

6. Healius Limited, Annual Report 2025. Lumus sale net proceeds A$795.2m; 41.3c special dividend (A$299.9m); new A$300m facility. https://cdn.prod.website-files.com/65d3ca771d58856db2f0cdff/68d6049d22617364c0b18eb1_Annual%20Report%202025%20FINAL.pdf

7. Simply Wall St, Healius (ASX:HLS) stock forecast & analysis. Agilex information memorandum; ~A$254m market value / "core pathology for next to nothing" framing; ACCC competition concerns re ACL bid. https://simplywall.st/stocks/au/healthcare/asx-hls/healius-shares/future

8. Investors in Healthcare, "Healius rejects A$2.12bn takeover bid from Partners Group" (May 2024). https://www.investorsinhealthcare.com/articles/australia-healius-rejects-a2-12bn-takeover-bid-from-partners-group/

9. Takeovers Panel, "Healius Limited: Panel Receives Application" (TP23-013, 2023). ACL off-market scrip bid, 0.74 ACL shares per Healius share. https://takeovers.gov.au/media-releases/tp23-013

10. MarketScreener, "Healius expects FY2026 group underlying EBIT of A$30m to A$35m" (13 May 2026). https://www.marketscreener.com/news/healius-expects-fy-2026-group-underlying-ebit-of-a-30-million-a-35-million-ce7f5bdfdc81f122